Narain, Co-founder, President & CTO of Berg Pharma said, That is obviously an unmet want in malignancy therapy and partnering with a world-course investigator and organization to advance BPM 31543 into clinical advancement is quite exciting. Affected individual recruitment for the Stage I study had started at the Evelyn H. Lauder Breasts Center at 66th Road and Second Avenue in NEW YORK. Detailed information on individual eligibility are available at identifier NCT01588522.. Berg Pharma initiates BPM 31543 clinical trial for chemotherapy-induced alopecia Berg Pharma, a Boston-based pharmaceutical company centered on advancement and discovery of fresh treatments in malignancy and metabolic diseases, announced the initiation of a scientific trial entitled Phase We Dose-Escalation Study to judge the Basic safety, Tolerability and Pharmacokinetics of a Topical Substance 31543 in Adult Individuals Receiving Chemotherapy for the treating Breast Cancer.Related StoriesNeurological testing accessibility and affordability: an interview with Dr Joseph HigginsGreater evidence-based help necessary for depressed employees – New report from THE TASK FoundationWHO focused on helping Nepal deliver healthcare to its citizens, says WHO South-East Asia Regional Director Locating cost-effective ways to increase access to care continues to be important, especially in this era of healthcare reform, and we are very happy to work together with these health care providers to greatly help coordinate comprehensive care for their patients, stated Dr.